急性卒中患者早期自适应伺服通气治疗对脑损伤演变和神经结局的影响:eSATIS随机对照试验方案
eSATIS是一项开放标签、多中心、随机对照试验,纳入急性缺血性卒中伴显著睡眠呼吸障碍(SDB)患者,比较立即自适应伺服通气(ASV)治疗与不治疗对梗死进展的影响。主要结局为卒中后3个月内磁共振成像评估的梗死进展,次要结局包括临床结局和生理参数。该试验旨在评估ASV治疗的可行性和疗效,为卒中急性期SDB诊治提供证据。
要点
- 急性缺血性卒中后首夜呼吸多导图筛查,AHI>20/h为显著SDB并随机分组。
- ASV组从卒中后第二夜开始治疗,主要结局为3个月内梗死进展。
- 该试验结果可能改变卒中急性期SDB的临床实践。
核心结论
- 该试验将提供ASV治疗在急性卒中伴SDB患者中的可行性和疗效信息,并评估SDB对卒中结局的影响。
研究设计与样本
- eSATIS为开放标签、多中心(4国6中心)、干预性、随机对照试验,纳入急性缺血性卒中伴显著SDB患者。
关键数值与推荐
- 显著SDB定义为呼吸多导图显示呼吸暂停低通气指数(AHI)>20/h,无SDB定义为AHI<5/h。
- 显著SDB患者随机分为ASV治疗组(ASV+)或不治疗组(ASV-),从卒中后第二夜开始。
- 所有患者在卒中后第1天(访视1)至第4-7天(访视4)以及第90±7天(访视6)进行临床、生理和磁共振成像检查。
临床怎么用
- 目前卒中急性期诊断和治疗SDB并非临床常规,该试验证据可能促使卒中诊疗改变并改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sleep-disordered breathing (SDB) is highly prevalent in acute ischaemic stroke and is associated with worse functional outcome and increased risk of recurrence. Recent meta-analyses suggest the possibility of beneficial effects of nocturnal ventilatory treatments (continuous positive airway pressure (CPAP) or adaptive servo-ventilation (ASV)) in stroke patients with SDB. The evidence for a favourable effect of early SDB treatment in acute stroke patients remains, however, uncertain. METHODS: eSATIS is an open-label, multicentre (6 centres in 4 countries), interventional, randomized controlled trial in patients with acute ischaemic stroke and significant SDB. Primary outcome of the study is the impact of immediate SDB treatment with non-invasive ASV on infarct progression measured with magnetic resonance imaging in the first 3 months after stroke. Secondary outcomes are the effects of immediate SDB treatment vs non-treatment on clinical outcome (independence in daily functioning, new cardio-/cerebrovascular events including death, cognition) and physiological parameters (blood pressure, endothelial functioning/arterial stiffness). After respiratory polygraphy in the first night after stroke, patients are classified as having significant SDB (apnoea-hypopnoea index (AHI) > 20/h) or no SDB (AHI < 5/h). Patients with significant SDB are randomized to treatment (ASV+ group) or no treatment (ASV- group) from the second night after stroke. In all patients, clinical, physiological and magnetic resonance imaging studies are performed between day 1 (visit 1) and days 4-7 (visit 4) and repeated at day 90 ± 7 (visit 6) after stroke. DISCUSSION: The trial will give information on the feasibility and efficacy of ASV treatment in patients with acute stroke and SDB and allows assessing the impact of SDB on stroke outcome. Diagnosing and treating SDB during the acute phase of stroke is not yet current medical practice. Evidence in favour of ASV treatment from a randomized multicentre trial may lead to a change in stroke care and to improved outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT02554487 , retrospectively registered on 16 September 2015 (actual study start date, 13 August 2015), and www.kofam.ch (SNCTP000001521).
引用
- Duss SB, Brill AK, Baillieul S, et al. Effect of early sleep apnoea treatment with adaptive servo-ventilation in acute stroke patients on cerebral lesion evolution and neurological outcomes: study protocol for a multicentre, randomized controlled, rater-blinded, clinical trial (eSATIS: early Sleep Apnoea Treatment in Stroke). Trials. 2021. PMID: 33482893. doi:10.1186/s13063-020-04977-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。